Proceedings of the inaugural Dark Genome Symposium: November 2022

Authors

• Jef D. Boeke, Institute for Systems Genetics, NYU Langone Health, New York, NY, 10016, USA.
• Kathleen H. Burns, Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
• Katherine B. Chiappinelli, Department of Microbiology, Immunology and Tropical Medicine, The George Washington University, Washington, DC, USA.
• Marie Classon, Pfizer Centre for Therapeutic Innovation, San Diego, USA.
• John M. Coffin, Department of Molecular Biology and Microbiology, Tufts University, Boston, MA, 02111, USA.
• Daniel D. DeCarvalho, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
• Joseph D. Dukes, Enara Bio Limited, Magdalen Centre, 1 Robert Robinson Avenue, The Oxford Science Park, Oxford, OX4 4GA, UK.
• Benjamin Greenbaum, Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
• George Kassiotis, Retroviral Immunology Laboratory, The Francis Crick Institute, London, UK.
• Sarah K. Knutson, Rome Therapeutics, 201 Brookline Avenue, Suite 1001, Boston, MA, USA.
• Arnold J. Levine, Simons Center for Systems Biology, Institute for Advanced Study, Princeton, NJ, USA.
• Avindra Nath, Section for Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
• Sophie Papa, Enara Bio Limited, Magdalen Centre, 1 Robert Robinson Avenue, The Oxford Science Park, Oxford, OX4 4GA, UK. sophie.papa@enarabio.com.
• Daniel Rios, Rome Therapeutics, 201 Brookline Avenue, Suite 1001, Boston, MA, USA.
• John Sedivy, Center on the Biology of Aging, Brown University, Providence, RI, USA.
• David T. Ting, Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Document Type

Journal Article

Publication Date

11-21-2023

Journal

Mobile DNA

Volume

14

Issue

1

DOI

10.1186/s13100-023-00306-5

Abstract

In November 2022 the first Dark Genome Symposium was held in Boston, USA. The meeting was hosted by Rome Therapeutics and Enara Bio, two biotechnology companies working on translating our growing understanding of this vast genetic landscape into therapies for human disease. The spirit and ambition of the meeting was one of shared knowledge, looking to strengthen the network of researchers engaged in the field. The meeting opened with a welcome from Rosana Kapeller and Kevin Pojasek followed by a first session of field defining talks from key academics in the space. A series of panels, bringing together academia and industry views, were then convened covering a wide range of pertinent topics. Finally, Richard Young and David Ting gave their views on the future direction and promise for patient impact inherent in the growing understanding of the Dark Genome.

APA Citation

Boeke, Jef D.; Burns, Kathleen H.; Chiappinelli, Katherine B.; Classon, Marie; Coffin, John M.; DeCarvalho, Daniel D.; Dukes, Joseph D.; Greenbaum, Benjamin; Kassiotis, George; Knutson, Sarah K.; Levine, Arnold J.; Nath, Avindra; Papa, Sophie; Rios, Daniel; Sedivy, John; and Ting, David T., "Proceedings of the inaugural Dark Genome Symposium: November 2022" (2023). GW Authored Works. Paper 3773.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/3773

Department

Microbiology, Immunology, and Tropical Medicine